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Abstract  
In difluoromethylornithine resistant L1210 cells stimulated to growth from quiescence, the selective K-opioidergic agonist trans-( +_ )- 
3,4-dichloro-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U-50488H) caused a dose dependent inhibition of the induction of ODC 
activity, with a half-maximal effect at about 1 /~M. U-50488H also provoked reduction of ODC mRNA level and increase of ODC 
turnover, as well as inhibition of cell growth. U-69593, another K-selective agonist, was only slightly effective. The action of U-50488H 
on ODC induction was not blocked by naloxone, /3-chlomaltrexamine or by the K-selective opioid antagonists Mr1452 and nor-bi- 
naltorphimine (nBNI). Actually Mr1452 and nBNI exerted some inhibitory effect. Furthermore, the separated enantiomers ( + )  and ( - )  
of U-50488H were similarly effective. The (-)cis-(1S,2 R)-U50488 stereoisomer, exhibiting low affinity for K and high affinity for o" 
receptors and carbetapentane, another o- ligand, also inhibited ODC induction, although less effectively than U-50488H. None of several 
other opioid ligands tested had significant effects on ODC induction. In conclusion, the inhibition of ODC expression by U-50488H does 
not involve classical, enantiospecific opioid receptors; rather, these results suggest the involvement of a distinct site of action linked to 
inhibition of lymphoid cell proliferation. 
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1. Introduction 
Numerous studies indicate that opioids play an impor- 
tant role in the regulation of  neural cell proliferation and 
act as DNA synthesis modulators during brain develop- 
ment ([1-3] and references therein). Alteration of  DNA 
synthesis by opioids is not restricted to neural cells as it 
occurs in lung and breast cancer cells, and in the immune 
system as well [4-7]. The proliferation capacity of  periph- 
eral blood lymphocytes is impaired in opiate addicts and 
Abbreviations: ODC, omithine decarboxylase; DFMO, a-difluoro- 
methylornithine; U-50488H, trans-(+_ )-3,4-dichloro-N-[2-(l- 
pyrrolidinyl)-cyclohexyl]benzeneacetamide methanesulfonate; nBNI, 
nor-binaltorphimine; /3-CNA, /3-chlornaltrexamine; U-69593, 
(5 a,7a,8/3 )-( + )-N-methyl-N-(7-[ 1-pirrolidinyl]- 1 -oxaspiro[4,5]deo-8-yl)- 
benzeneacetamide; DAMGO, [D-Ala2,N-Me-Phe4,GlyS-ol]-enkephalin; 
Mr1452,(-)-N-(3-furylmethyl)-a-normetazocine methanesulfonate; PCR, 
polymerase chain reaction. 
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various endogenous and synthetic opioids can affect DNA 
synthesis and other biochemical and immune responses of 
lymphoid cells [6-8]. These various, even opposite effects 
may be mediated by different kinds of  opioid receptors 
like the /~, 8 and K types, which have been described in 
lymphoid cells [6-9]. However some effects do not appear 
to involve these classical opioid receptors since were not 
blocked by naloxone [6,7]. Naloxone insensitive binding 
sites for opioids have been described also in neural and 
other nonneural cells [10-13]. 
Ornithine decarboxylase (ODC), the first and key en- 
zyme in polyamine biosynthesis, is essential for cell prolif- 
eration and is induced following growth stimuli [14-16]. 
ODC gene is now recognized as an early response gene 
required for entry into S phase of  the cell cycle and, 
according to a recent paper [17], as a proto-oncogene. 
ODC expression can be finely regulated at transcriptional, 
translational and post-translational levels by numerous hor- 
mones, growth factors and cytokines [ 16]. However only a 
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few studies have been dedicated to the effects of opiates 
and opioid peptides on ODC regulation. In vivo adminis- 
tration of morphine, methadone, /3-endorphin or acetyl-/3- 
endorphin was found to increase or decrease ODC activity 
in some tissues, particularly of developing rats [18-21]. In 
these in vivo experiments some effects may have been 
indirect and mediated by the nervous or endocrine systems. 
In cultured neuroblastoma x glioma hybrid cells, micromo- 
lar concentration of morphine, levarphanol and etorphine 
inhibited the induction of ODC activity [22], whereas in 
hippocampal slices /3-endo:rphin, acetyl-/3-endorphin and 
ala-enkephalinamide potentiated the stimulation of ODC 
activity [23]. 
In order to ascertain if opioids may affect ODC expres- 
sion in lymphoid cells, we have utilized a line of L1210 
cells selected for resistance to the ODC inhibitor difluo- 
romethylornithine (L 1210-DFMO r) [24]. Because of gene 
amplification, these cells can express ODC at very high 
levels, while maintaining the usual mechanisms of regula- 
tion of the enzyme. 
2. Materials and methods 
2.1. Materials 
with a ABI 391 DNA synthesizer (Applied Biosystems, 
Cheshire, UK) and then purified by reverse phase HPLC. 
The PCRs were carried out in a Cetus DNA thermal cycler 
(Perkin Elmer). Capillary electrophoresis was performed in 
a P /ACE System 2100 (Beckman Instruments, Fullertone, 
CA). 
2.2. Cell culture and treatment 
Mouse L1210-DFMO r cells were routinely grown in the 
presence of 20 mM DFMO in RPMI 1640 medium con- 
taining fetal-calf serum, antibiotics and /3-mercapto- 
ethanol, as described by Persson et al. [20]. For experi- 
ments, cells were shifted to, and maintained in, a DFMO- 
free medium for at least 15 days. Then, quiescent cells 
(cell density > 2 • 106/ml) were seeded at 2.  105/ml in 
fresh medium containing 10% serum and treated with 
opioids or other drugs as indicated. Wild-type L1210 cells 
were utilized under the same experimental conditions. Cell 
viability was checked by the trypan blue exclusion test. At 
the time indicated after seeding, cells were harvested and 
washed with phosphate-buffered saline. 
2.3. Determination o f  ODC activity and immunoreactive 
protein content 
L 1210-DFMO r cells and antibodies against mouse ODC 
were a generous gift from Dr. L. Persson (University of 
Lund, Lund, Sweden). L-[l-14C]Ornithine was purchased 
from ICN Biomedicals (Irvine, CA) and DL-[3,4-3H]DFMO 
from DuPont-New England Nuclear (Boston, MA). DFMO 
was kindly provided by the Merrell Dow Research Insti- 
tute (Strasbourg, France). Trans-(++_)-3,4-dichloro-N-[2- 
(1-pyrolidinyl)cyclohexyl]benzeneacetamide methanesul- 
fonate (U-50488H) and the separated trans ( + )  and ( - )  
enantiomers of U-50488H (U-53444E and U-53445E) were 
generously given by the Upjohn Co. (Kalamazoo, MI). 
( - ) - c i s - (1S ,2R) -U50488 ,  nor-binaltor-phimine (nBNI), 
/3-chlornaltrexamine (/3-CNA), baloperidol, carbetapen- 
tane and metaphit methanesulfonate were from RBI 
(Natick, MA). Naloxone, (5 a,7c~,8 /3 )-( + )-N-methyl-N- 
(7-[l-pirrolidinyl]-l-oxaspiro[4,5]dec-8-yl) benzeneac- 
etamide (U-69593), methanesulfonic acid, tetrodotoxin, 
carbachol, atropine and [D-Ala 2, N-Me-Phe 4, GlyCol] 
enkephalin (DAMGO) were purchased from Sigma Chemi- 
cal Co. (St. Louis, MO). Dynorpbin A (1-13) was from 
Peninsula Laboratories (Belmont, CA) and (-)-N-(3-Fur- 
ylmethyl)a-normetazocine methanesulfonate (Mr1452) 
from Boheringer Ingelheim Pharmaceuticals, Inc. (Ridge- 
field, CT). Leu-enkephalin and met-enkephalin were sup- 
plied by Serva (Heidelberg, Germany) and human /3-en- 
dorphin by Fluka (Buchs, Switzerland). Molecular biology 
products were purchased from Boheringer Mannheim 
(Mannheim, Germany), Pharmacia (Uppsala, Sweden), 
Perkin Elmer (Norwalk, CT) or Sigma. Oligonucleotide 
primers for reverse transcriptase/PCR were synthesized 
Cell extracts were prepared and assayed for ODC activ- 
ity and immunoreactive content as previously described 
[25]. ODC activity was determined in the presence of 
L-[1-14C]ornithine by measuring the amount of CO 2 re- 
leased [25,26], and is expressed as U / m g  of protein, 
where 1 unit corresponds to 1 nmol CO2/h incubation. 
U-50488H did not affect ODC activity significantly when 
added directly to the assay mixture at the concentration of 
10 /xM. The content of immunoreactive ODC protein was 
determined by radioimmunoassay by using [3H]DFMO- 
labeled ODC, as described by Seely and Pegg [27]. Protein 
content was measured in cell extracts according to Brad- 
ford [28]. 
2.4. Detection o f  ODC mRNA 
ODC mRNA was detected in L1210-DFMO r cells by 
combined reverse transcriptase/PCR analysis. Total RNA 
was isolated from about 10 7 cells using the guanidinium 
thiocyanate method [29]. Any contaminating DNA was 
removed by DNase treatment essentially as described by 
Halmekyto et al. [30]. This treatment was necessary be- 
cause mouse genome contains many pseudogenes for ODC 
[15]. cDNA synthesis and PCR were performed by the 
same enzyme, rTth DNA polymerase (Perkin Elmer) ac- 
cording to manifacturers' instructions. The reaction mix- 
ture contained 0.25 /zg of total RNA extracted from cells, 
5 U of rTth DNA polymerase, 0.2 mM each dNTP and 
100 pmol of each primer in a final volume of 50 /zl. The 
PCR primers for mature ODC mRNA were designed so as 
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to yield a PCR product of 224 nt. The 5' primer (5'- 
T C A T A G C T G A G C C A G G C A G A T A - 3 ' )  was targeted to a 
sequence in exon 9 of  mouse ODC mRNA and the 3' 
primer (5 ' -CTTGGGTCTCTTCTGCAGC-3 ' )  recognized a 
sequence at the junction of  exons 10 and 11. The reverse 
t ranscr ip tase /PCR consisted of  a reverse transcriptase 
phase (60°C for 30 min, 94°C for 2 min) followed by 
amplification (94°C for 45 s, 60°C for 75 s). Each sample 
was amplified at a growing number of  cycles (in the range 
from 15 to 27 cycles). PCR products were either visualized 
by ethidium bromide fluorescence after separation on 1.5% 
agarose gel electrophoresis or quantitated by capillary 
electrophoresis coupled to laser-induced fluorescence. As 
for capillary electrophoresis, PCR products were directly 
separated at 35°C in a 27 cm total length × 0.1 mm I.D. 
deactivated fused-sil ica capillary (Beckman Instruments). 
Before separation, the capillary was equilibrated for 30 
min with a running solution containing 89 mM Tr i s /bo r i c  
acid, 2 mM EDTA (pH 8.5), 0.5% hydroxy-propyl-  
methyl-cellulose (4,000 cps) and 3 / z l / m l  of  the fluores- 
cent intercalator YOPRO (Molecular  Probes, Eugene, OR). 
The samples were injected by pressure for 5 s and sepa- 
rated within 20 min at a constant voltage of 4 kV. Detec- 
tion was performed by a sensitive laser-induced fluores- 
cence detector equipped with an argon lamp. Values were 
corrected by comparison with a 525 bp internal standard 
(Bio Ventures). The high sensitivity of  this technique 
allowed detection of  samples not visualized on agarose 
gels. For the determination of  the relative amounts of  ODC 
mRNA, kinetic PCR analysis was performed according to 
Sugiyama et al. [31]: logarithms of  values obtained by 
capillary electrophoresis were plotted against the number 
of PCR amplification cycles and extrapolation of  the 
straight lines (correlation coefficient r = 0.99) to zero 
amplification cycle gave the amounts of  ODC mRNA 
before the PCR amplification. 
2.5. Statistical analysis 
Significant differences between groups were assessed 
by Student 's  t-test for independent measurements or, where 
indicated, by paired t-tests or two-way ANOVA.  
3.  R e s u l t s  
3.1. Effects o f  U-50488H and other opioid agonists 
We have previously shown that dilution of high density 
L1210-DFMO r cells in fresh medium containing serum 
leads to induction of  ODC activity and immunoreactive 
ODC protein, supported by an accumulation of  ODC 
mRNA [32]. Several opioid agonists, natural or synthetic 
and with various receptor type specificity, were tested for 
the ability to modulate the induction of  ODC activity. 
Table 1 shows that only the K selective agonists U-50488H 
Table 1 
Effect of some opioid receptor agonists 
in L1210-DFMO r cells 
on the induction of ODC activity 
Opioid agonist ODC activity 
(% of control) 
morphine 97.4 + 12.3 
dynorphin A (1-13) 97.0+ 8.9 
/3-endorphin 96.5 + 1.4 
Leu-enkephalin 102.9 + 4.6 
Met-enkephalin 100.0 + 0.3 
DAMGO 100.2 +__ 14.2 
U-50488H 10.9 + 3.7 * ~ 
U-69593 83.5 + 7.3 * 
High density L1210-DFMO r cells were diluted in fresh medium contain- 
ing serum, supplemented with opioid agonists at the concentration of 
10/xM and harvested after 16 h. Results are means_S.D, of three 
separate determinations. * * P < 0.01 and * P < 0.05, significantly dif- 
ferent from control. 
and U-69593 were able to inhibit the induction of  the 
enzyme significantly. As shown in Fig. 1, both drugs 
exerted a dose dependent effect on ODC induction, but 
U-50488H was far more effective with a half-maximal 
effect at about 1 ~ M  and an inhibition by about 90% at 10 
/zM. A significant effect was observed at a concentration 
of  U-50488H as low as 0.2 /zM ( P  < 0.01 vs. control). 
Since U-50488H is provided as a methanesulfonate salt, 
control experiments were performed with methanesulfonic 
acid alone (10 /zM) and showed no significant effect on 
ODC induction. It should be noted that treatment with 10 
/xM U-50488H for 16 h, as employed in the previous 
experiments,  did not affect cell viability; instead U-50488H 
(10 /xM) inhibited cell growth markedly (Fig. 2). The 
time-course of the induction of  ODC activity in the ab- 
sence or in the presence of  1 0 / x M  U-50488H is shown in 
Fig. 3A. ODC induction was inhibited after 4 h of  treat- 
ment ( P  < 0.05, significantly different from control) and 
remained low thereafter. U-50488H was effective even 
when administered 16 h after cell seeding to cells contain- 
ing high levels of  the enzyme (Fig. 3B): ODC activity was 
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Fig. 1. Effect of increasing concentration of U-50488H (panel A) and 
U-69593 (panel B) on ODC induction in L1210-DFMO r cells. High 
density cells were diluted in fresh medium containing serum and treated 
with different concentrations of the r agonists. Cells were harvested 16 h 
after seeding. Results are means + S.D. of three separate determinations. 
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Fig. 2. Effect of U-50488H on growth curve of L1210-DFMO r cells. 
Cells were diluted and incubated in the absence (O)  or presence (O)  of 
10 /zM U-50488H. Results represent means-t-S.D, of three separate 
flasks. 
less than 50% of control already after 2 h of treatment 
( P  < 0.01) and then continued to decline. 
The negative effect of U-50488H on the induction of 
ODC activity was accompanied by a marked decrease of 
immunoreactive ODC protein (data not shown), and by a 
reduction of ODC mRNA, as detected by combined re- 
verse transcriptase/PCR analysis (Fig. 4). In fact the level 
of ODC mRNA, very low in quiescent cells, increased 
after dilution of the cells, and U-50488H treatment reduced 
this increase. Quantitation of ODC mRNA content by 
kinetic PCR followed by capillary electrophoresis (see 
Materials and Methods) :showed that the level of the 
messenger was about 40% and 20% of control after 8 h 
and 16 h with U-50488H, respectively. In addition, a 
2.7-fold increase in the ODC decay following cyclohex- 
imide was observed in cells treated for 16 h with U-50488H 
(Fig. 5A). Since U-50488H provoked a rapid decrease of 
preinduced ODC activity (Fig. 3B), ODC turnover was 
analyzed even after a shoal treatment with the drug. Fig. 
5B shows that under these conditions U-50488H affected 
ODC turnover slightly. 
Finally, the effect of U-50488H on the induction of 
ODC activity in wild type L1210 cells was also examined: 
ODC activity was 6.7 U / m g  protein 16 h after cell 
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Fig. 3. Effect of U-50488H on the time-course of ODC activity in 
L1210-DFMO r cells. Panel A: cells were diluted and immediately treated 
with 10 /xM U-50488H. Panel B: cells were diluted and, after 16 h, 
treated with 10 ~M U-50488H. (O),  control cells; (O),  U-50488H 
treated cells. Results are means + S.D. of three separate determinations. 
A B 
1 2 3 4 1 2 3 
Fig. 4. Effect of U-50488H on the expression of ODC mRNA. LI210- 
DFMO r cells were harvested and analyzed for ODC mRNA by reverse 
transcriptase/PCR. PCR products (224 bp) were visualized by ethidium 
bromide fluorescence after separation on gel agarose electrophoresis. 
Panel A: lane 1, molecular size markers (BglI and Hinfl pBR328 DNA 
fragments of 2176, 1766, 1230, 1033, 653, 517, 453, 394, 298, 234, 220 
and 154 bp); lane 2, high density quiescent cells; lane 3, control cell (8 h 
after dilution); lane 4, cells treated with 10/xM U-50488H for 8 h. Panel 
B: lane 1, control cells (16 h after dilution); lane 2, cells treated with 10 
/xM U-50488H for 16 h; lane 3, molecular size markers. 
dilution (control) and 3.6 and 1.4 U / m g  protein in cells 
treated with 10 /zM and 50 /zM U-50488H, respectively. 
3.2. Effects of opioid antagonists and stereospecificity of 
U-50488H 
Since U-50488H is considered a selective K opioid 
agonist, some experiments were carried out to verify if the 
effects on ODC induction could be mediated by classical 
~ lO0.Oq 
~6 10.0 
~o 1.0 
o 
o 
••0A 
lO0"Oq 
10.0 
1.0 
0.1 ' ' ' 0.1 
0 30 60 90 
~ms after cycloheximide (min) 
i , r 
0 30 60 90 
TTme after cycloheximide (re|n) 
Fig. 5. Effect of U-50488H on the rate of ODC decay. Panel A: cells 
were diluted and half of them immediately treated with 10/xM U-50488H. 
After 16 h, 0.2 mM cycloheximide was added to all the cells and samples 
were removed at 30-min intervals. Average ODC activity of U-50488H 
treated cells at time zero was 9.5% of control. Panel B: cells were diluted 
and, after 16 h, half of them were treated with 10 /xM U-50488H; 1 h 
later, 0.2 mM cycloheximide was added to all the cells and samples were 
removed at 30 min intervals. Average ODC activity of U-50488H treated 
cells at time zero was 70.4% of control. (O), control cells; (O),  
U-50448H treated cells. The results represent means of two separate 
experiments. U-50488H treatment affected ODC decay significantly in 
each experimental condition (P < 0.05 vs. control by paired t-test). 
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Table 2 
Effect of some opioid antagonists on the U-50488H inhibition of ODC 
induction 
Antagonist  Conch. ODC activity (% of control) 
( /xM)  U-50488H conch.( /xM) 
0 1 2 
none - 100.0-4- 6.9 63.25:3.0 36.3_+2.2 
naloxone 5 89 .3+  2.7 64.1 _+0.5 36.95:4.3 
20 103.55:14 66.75:5.4 36.65:4.8 
Mr1452 1 93.1 _+ 12 67.0_+ 1.0 n.d. 
10 74.3_+ 5.9 57.65:6.0 26.1 _+3.4 
nBNI 2 92.4_+ 1.1 63.24-6.3 30.7_+4.7 
10 71.9_+ 5.1 52.95:5.1 23.2_+3.0 
LI210-DFMO r cells were diluted and treated with U-50488H in the 
presence or absence of opioid antagonists. Cells were harvested 8 h after 
seeding. Results are mean 5: S.D. of three determinations; n.d., not deter- 
mined. Mr1452 and nBNI exerted a significant effect on ODC induction 
( P  < 0.01 by two-way ANOVA).  
opioid receptors. Table 2 shows that neither naloxone, nor 
the selective K antagonists Mr1452 and nBNI were able to 
block the ODC inhibiting effect of U-50488H in L1210- 
DFMO r cells. Actually the K selective antagonists showed 
a negative effect, although less marked than U-50488H. 
Pretreatment with the alkylating, irreversible opioid antag- 
onist /3-CNA (0.5 /xM) was also completely ineffective in 
blocking the U-50488H action on ODC and had no effect 
per se. Furthermore the separated enantiomers ( - )  and 
( + )  of U-50488H (U-53444E and U-53445E) were simi- 
larly effective and inhibited ODC induction to a degree 
comparable to the racemic compound (U-50488H) (results 
not shown). The (-)-cis-(lS,2R)-U50488 stereoisomer, 
exhibiting preference for o- receptors, and carbetapentane, 
another o- agonist, were also effective, although to a lesser 
extent compared to U-50488H (Table 3). Other pharmaco- 
logical agents tested did not affect ODC activity (tetro- 
Table 3 
Effect of various pharmacological agents on 
activity 
the induction of ODC 
Agent concn. ODC activity 
( ~ M )  (% of control) 
U-50488H 1 51.4 + 10.1 * * 
10 11.4+2.1 ** 
( - )-cis-(l S,2 R)-U-50488 1 94.1 _+ 1.2 
10 31.9_+3.3 * * 
Carbetapentane 1 85.6 _+ 5.8 * 
10 42.9_+3.6 * x 
Tetrodotoxin 2 106.2 5:4.8 
10 108.95:2.8 
Carbachol 10 99.4 _+ 8.2 
100 97.3 _+ 2.1 
Atropine 10 84.2 _+ 1.4 * 
LI210-DFMO r cells were diluted and treated with the indicated agents. 
Cells were harvested 16 h after seeding. Results are means 5: S.D. of three 
determinations. * * P < 0.01 and * P < 0.05, significantly different from 
control. In addition, the effects of carbetapentane or ( - ) - c i s - ( l S ,2R) -  
U50488 were significantly different from the effect of U-50488H ( P  < 
0.01 by two-way ANOVA). 
dotoxin, carbachol), or, in the case of atropine, reduce it 
only slightly. 
4. Discussion 
This research shows that U-50488H, a selective K- 
agonist widely used in the pharmacological and biochemi- 
cal research [33], can inhibit the expression of ODC activ- 
ity and the growth of L1210-DFMO r cells. The inhibiting 
effect of U-50488H on ODC activity appeared to result 
from both a reduction in the level of ODC mRNA and an 
acceleration of ODC turnover. Concentrations similar to 
those used in the present research or even higher concen- 
trations of U-50488H have been employed in in vitro 
systems with intact cells or sinaptosomes to show signifi- 
cant effects [2,3,34-36]. Interestingly, U-50488H at 10 
/xM was found to increase thymidine incorporation into 
DNA by 60% in rat spinal cord-dorsal root ganglion 
co-cultures [3]. In another study with fetal rat brain cell 
aggregates, U-50488H (1 /xM) either increased or de- 
creased DNA synthesis according to the stage of brain 
development [2]. 
U-69593, another K opioid selective agonist [2], was 
slightly effective in the present study; however the effects 
of U-50488H on ODC induction do not appear to involve 
K or other classical opioid receptors, lacking both enan- 
tiospecificity and antagonist sensitivity. Actually, the K- 
antagonists nBNI and Mr1452 were themselves inhibitory. 
Other effects of U-50488H not mediated by classical opi- 
oid receptors have been reported [11,37-40]. Interestingly, 
U-50488H inhibited nicotine-induced Ca2+-uptake into 
cultured adrenal medullary cells with a ICs0 of 1 /zM and 
none of various opioid antagonists examined was able to 
reverse this effect [11]. Furthermore the K antagonist 
Mr2266 also produced a marked inhibition of Ca 2+ up- 
take. 
Although U-50488H shows a marked preference for 
K-receptors, it also can bind the naloxone-insensitive o" 
sites, the ( - )  enantiomer exhibiting a slightly higher 
affinity than the ( + )  compound [41]. Even if o- receptors 
have been identified in lymphoid cells [42], the U-50488H 
effect on ODC does not seem to be mediated by o" sites. In 
fact the ( - )-cis-U-50488 isomer, exhibiting a high affinity 
for cr receptors [41], proved to be less potent than the trans 
isomers. Furthermore haloperidol, which has been reported 
to antagonize o- effects of U-50488H [43] and metaphit, 
which can act as an irreversible inhibitor of o- receptors 
[44], could not block the U-50488H effect on ODC (data 
not shown). These findings however do not role out the 
possibility that o--sites may be involved in the control of 
ODC expression, as suggested by the efficacy of carbe- 
tapentane, another cr ligand [12]. 
It is possible to speculate that in lymphoid cells U- 
50488H may bind to a receptor whose natural ligand is 
unknown. Recently an atypical opioid receptor has been 
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cloned and characterized [44]: it did not  b ind  any of  the 
prototypical  endogenous  opioids ( /3-endorphin ,  enkephal in  
and dynorphin)  but  only  the non  selective opioid l igand 
etorphine at relatively high concentrat ion.  As an alternative 
speculation,  U-50488H may b ind  to some post-receptor 
site. For  instance, Peryasamy et al. [45] hypothesized that 
U-50488H inhibi ted carbachol-s t imulated phosphoinosi t ide 
turnover  in rat h ippocampal  slices through a direct interac- 
tion with a G protein. St imulat ion of  some muscar inic  
receptors has been shown to have mitogenic  effects [46,47]; 
however,  in our  condit ions,  atropine was hardly effective 
in reducing ODC induct ion and carbachol neither affected 
O D C induct ion nor  prew,~nted the U-50488H inhibi t ing 
effect (not shown). Another  possible naloxone insensi t ive 
site of  action of  U-50488H,  i.e. sodium channels  [38-40] ,  
seems to be excluded by the lack of effect of  tetrodotoxin, 
which on the contrary reproduced most  of  the cardio- 
vascular  actions of U-50488H [39]. 
Final ly,  wild type L1210 cells were also sensit ive to 
U-50488H treatment,  indicat ing that this phenomenon  is 
not  l imited to a particular, ODC overproducing cell line. 
However  higher concentra t ions  of U-50488H were re- 
quired to achieve a marked inhibi t ion of  ODC induction.  
Al though the reason for thJis difference is unknown,  it may 
be noted that L I 2 1 0 - D F M O  r cells contain higher levels of  
po lyamines  [24], which may modula te  signal t ransduct ion 
pathways [48] and regulate ODC itself [15]. Quite recently, 
we have found that micromolar  concentra t ions  of  U- 
50488H inhibi t  D N A  synthesis in both L1210 cell lines 
and in thymocytes  (thyrnic lymphocytes) .  Furthermore,  
U-50488H also inhibi ted mitogen-el ic i ted ODC induct ion 
and promote  apoptosis of thymocytes.  None  of  these ef- 
fects were antagonized by naloxone (manuscr ipt  in prepa- 
ration). 
In conclus ion  this research shows that U-50488H and 
some related K-specific l igands can inhibi t  ODC induct ion 
in L1210 cells through a site dist inct  from the classical, 
stereospecific opioid receptors, and l inked to inhibi t ion of  
lymphoid  cell proliferation. 
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